Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa

Overview

Journal J Urol

Publisher Wolters Kluwer

Specialty Urology

Date 2013 Mar 19

PMID 23500642

Citations 17

Authors

Wolfgang Jager

Yutaka Horiguchi

Jay Shah

Tetsutaro Hayashi

Shannon Awrey

Kilian M Gust

Boris A Hadaschik

Yoshiyuki Matsui

Shawn Anderson

Robert H Bell

Susan Ettinger

Alan I So

Martin E Gleave

I-Ling Lee

Colin P Dinney

Masaaki Tachibana

David J McConkey

Peter C Black

Affiliations

Soon will be listed here.

Abstract

Purpose: KU7 is a popular urothelial carcinoma cell line that was isolated from the bladder of a patient at Keio University in 1980. It has subsequently been widely used in laboratories around the world. We describe how routine cell line authentication revealed that KU7 was cross contaminated almost 30 years ago with HeLa, a cervical carcinoma cell line.

Materials And Methods: Presumed KU7 clones dating from 1984 to 1999 were provided by M.D. Anderson Cancer Center, Vancouver Prostate Centre, Kyoto University, Tokyo Medical University and Keio University. HeLa was obtained from ATCC. Genomic DNA was isolated and short tandem repeat analysis was performed at the M.D. Anderson Cancer Center Characterized Cell Line Core Facility, Johns Hopkins University Fragment Analysis Facility and RIKEN BioResource Center, Ibaraki, Japan. Comparative genomic hybridization was performed on a platform (Agilent Technologies, Santa Clara, California) at Vancouver Prostate Centre.

Results: The short tandem repeat profile of all KU7 clones was an exact match with that of HeLa. Comparative genomic hybridization of all samples revealed an abundance of shared chromosomal aberrations. Slight differences in some genomic areas were explained by genomic drift in different KU7 clones separated by many years.

Conclusions: Our analysis identified that cross contamination of KU7 with HeLa occurred before 1984 at the source institution. All KU7 clones in the urological literature should be considered HeLa and experimental results should be viewed in this light. Our results emphasize the need to authenticate cell lines in oncological research.

Citing Articles

Molecular characterization and genetic authentication assay for Anopheles 'hemocyte-like' cell lines 4a-3A and 4a-3B.

Eggleston H, Njoya K, Anderson C, Holm I, Eiglmeier K, Liang J Parasit Vectors. 2022; 15(1):465.

PMID: 36514125 PMC: 9749150. DOI: 10.1186/s13071-022-05590-3.

Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.

Raven P, DCosta N, Moskalev I, Tan Z, Frees S, Chavez-Munoz C Am J Clin Exp Urol. 2019; 6(6):245-259.

PMID: 30697580 PMC: 6334200.

Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.

Zuiverloon T, de Jong F, Costello J, Theodorescu D Bladder Cancer. 2018; 4(2):169-183.

PMID: 29732388 PMC: 5929350. DOI: 10.3233/BLC-180167.

An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.

Huebner D, Rieger C, Bergmann R, Ullrich M, Meister S, Toma M BMC Cancer. 2017; 17(1):790.

PMID: 29169339 PMC: 5701455. DOI: 10.1186/s12885-017-3778-3.

The establishment of a growth-controllable orthotopic bladder cancer model through the down-regulation of c-myc expression.

Seo H, Shin S, Jung N, Kwon W, Jeong K, Lee S Oncotarget. 2017; 8(31):50500-50509.

PMID: 28881578 PMC: 5584157. DOI: 10.18632/oncotarget.10784.

References

Jones Jr H . Record of the first physician to see Henrietta Lacks at the Johns Hopkins Hospital: history of the beginning of the HeLa cell line. Am J Obstet Gynecol. 1997; 176(6):S227-8. DOI: 10.1016/s0002-9378(97)70379-x. View

Hadaschik B, Black P, Sea J, Metwalli A, Fazli L, Dinney C . A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int. 2007; 100(6):1377-84. DOI: 10.1111/j.1464-410X.2007.07165.x. View

SCHERER W, SYVERTON J, GEY G . Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med. 1953; 97(5):695-710. PMC: 2136303. DOI: 10.1084/jem.97.5.695. View

OToole C, Povey S, Hepburn P, FRANKS L . Identity of some human bladder cancer cell lines. Nature. 1983; 301(5899):429-30. DOI: 10.1038/301429a0. View

Shibayama T, Tachibana M, Deguchi N, JITSUKAWA S, Tazaki H . SCID mice: a suitable model for experimental studies of urologic malignancies. J Urol. 1991; 146(4):1136-7. DOI: 10.1016/s0022-5347(17)38025-4. View

Adam L, Black P, Kassouf W, Eve B, McConkey D, Munsell M . Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol. 2007; 177(5):1900-6. DOI: 10.1016/j.juro.2007.01.003. View

Tanaka M, Gee J, de la Cerda J, Rosser C, Zhou J, Benedict W . Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J Urol. 2003; 170(3):975-8. DOI: 10.1097/01.ju.0000073209.65128.c1. View

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K . Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest. 2005; 115(4):978-85. PMC: 1062892. DOI: 10.1172/JCI23043. View

10.

Tazaki H, Tachibana M . [Studies on KU-1 and KU-7 cells as an in vitro model of human transitional cell carcinoma of urinary bladder]. Hum Cell. 1988; 1(1):78-83. View

11.

Lucey B, Nelson-Rees W, Hutchins G . Henrietta Lacks, HeLa cells, and cell culture contamination. Arch Pathol Lab Med. 2009; 133(9):1463-7. DOI: 10.5858/133.9.1463. View

12.

Masramon L, Vendrell E, Tarafa G, Capella G, Miro R, Ribas M . Genetic instability and divergence of clonal populations in colon cancer cells in vitro. J Cell Sci. 2006; 119(Pt 8):1477-82. DOI: 10.1242/jcs.02871. View

13.

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59(6):997-1008. DOI: 10.1016/j.eururo.2011.03.017. View

14.

Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H, Murai M . Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer. 1997; 76(2):206-10. PMC: 2223948. DOI: 10.1038/bjc.1997.363. View

15.

Gartler S . Genetic markers as tracers in cell culture. Natl Cancer Inst Monogr. 1967; 26:167-95. View

16.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

17.

. Cell line misidentification: the beginning of the end. Nat Rev Cancer. 2010; 10(6):441-8. DOI: 10.1038/nrc2852. View

18.

Benedict W, Tao Z, Kim C, Zhang X, Zhou J, Adam L . Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther. 2004; 10(3):525-32. DOI: 10.1016/j.ymthe.2004.05.027. View

19.

Masters J . HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer. 2002; 2(4):315-9. DOI: 10.1038/nrc775. View

20.

van der Horst G, van Asten J, Figdor A, van den Hoogen C, Cheung H, Bevers R . Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis. Eur Urol. 2011; 60(2):337-43. DOI: 10.1016/j.eururo.2011.05.005. View